I agree there will be some company defining announcements in the next few months TB, however I think we need to temper expectations regarding the sale of Hervax.
Any potential suitor will need to stump up hundreds of millions just to complete the required phase 3 trial with no guarantee of FDA approval. It's also well known that we have no capacity to take it any further so we're not in a strong negotiating position. My discussions with management have led me to form the opinion that if there is a deal it will likely be heavily back ended with milestone payments along the way and a minimal upfront. This is the only real viable option for a potential purchaser IMO.
Of course I would love a cheque for a billion upfront but IMO highly unlikely. Personally, even though they are great products, I view any deal from the Bcell platform as just a bonus.
I'm here for Oncarlytics, CF33 and now Azer Cell, which if successful obtaining FDA approval will completely revolutionize cancer treatment as we know it. That'll do me.
IMU Price at posting:
11.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)